Navigation Links
Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia

A new study is providing scientists with a better understanding of why some pediatric acute lymphoblastic leukemia (ALL) patients fail to respond to treatment even when existing clinical predictive criteria point towards a positive treatment outcome. The research, published in the April issue of Cancer Cell, is likely to facilitate development of new strategies to combat drug resistance and treatment failure for children with ALL.

Nearly 80% of children with ALL are cured following chemotherapeutic treatment. However, the remaining 20% often exhibit drug resistance and treatment failure that is poorly understood. In some cases, patients are resistant to multiple drugs that have very little structural similarity, suggesting that the mechanisms for drug cross-resistance are probably not the same as mechanisms underlying resistance to a single drug. Dr. William E. Evans from St. Jude Children's Research Hospital and colleagues used a comprehensive genetic screening technique to search for genes that are differentially expressed in ALL cells that demonstrated cross-resistance to two or more commonly used chemotherapeutic agents.

The researchers identified several genes that were differentially expressed in ALL cells that exhibited de novo cross resistance to four widely used antileukemic agents. They went on to investigate the relationship of these genes to treatment outcome in ALL patients and found that expression of the genes was associated with treatment outcome and could be used to identify a subset of patients with a markedly inferior response to treatment. In addition, the findings revealed a previously unrecognized phenotype characterized by discordant resistance to two widely used and mechanistically distinct antileukemic agents and provided new information about the cellular mechanisms involved in disparate response to these drugs.

Specific genetic signatures related to ALL treatment failure and chemotherapeutic cross-resistance were mor
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
2. Drug-resistant bacteria on poultry products differ by brand
3. Genetic discovery could lead to drought-resistant plants
4. UF researchers kill resistant bugs one bandage at a time
5. DDT-resistant insects have additional genetic advantage that helps resistance spread
6. Drug resistant avian influenza viruses more common in Southeast Asia than North America
7. New molecule may aid in production of biofuels and fungi-resistant plants
8. Reducing antibiotic use lowers rates of drug-resistant bacteria
9. New class of antibiotics effective against drug-resistant bacteria discovered in fungi
10. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
11. Virginia Tech helping to develop higher quality, disease-resistant wheat varieties
Post Your Comments:
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... list of 235 planthoppers from Iran is recorded along with ... Iranian Auchenorrhyncha during last 100 years. In addition to the ... transferring one species at family level is proposed. The study ... . Planthoppers are studied relatively little, but are ...
... on Centers for Disease Control and Prevention and other ... 30 years, we recognize the importance of reaching our ... with teachers having to incorporate more and more learning ... leave room for nutrition education in elementary schools? ...
... antibody developed by MassBiologics of the University of Massachusetts ... C virus (HCV) infection undergoing liver transplantation significantly suppressed ... and delayed the time to viral rebound. Results from ... this week at The Liver Meeting, the annual meeting ...
Cached Biology News:Cooking in the classroom to fight childhood obesity 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... 1, 2011 Investor Uprising ( www.investoruprising.com ) has ... guide to the best biotech Exchange Traded Funds (ETFs) ... users of the Website. (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) ... ongoing biotech bull market, identifying the leading biotech mutual ...
... June 1, 2011 Aaron Mitchell, managing principal at global ... top 25 consultants of 2011 by Consulting Magazine. Mitchell was ... biotech firm over several years and during a major, recent ... one of the top consultants," said Mitchell, who has more ...
... June 1, 2011 Reportlinker.com announces that ... in its catalogue: Osteosarcoma ... to 2017 http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
Cached Biology Technology:Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Managing Principal at ZS Associates Named One of Consulting Magazine's Top 25 Consultants of 2011 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10
...
... Mouse Monoclonal to L1 Cell Adhesion ... which is located in Xq28, is involved ... of the aqueduct of Sylvius); 2) MASA ... and 3) SPG1 (spastic paraplegia). ...
...
... One-Step FP Standardization Kit is used ... fluorescence polarization values of fluorescein solutions ... 2000 System. It also allows users ... by their instrument to the expected ...
Biology Products: